Johnson & Johnson (NYSE:JNJ)’s Lung Cancer Initiative has signed a licensing and development accord to access narrow-spectrum Kinase inhibitors of Pulmatrix Inc (NASDAQ:PULM). As per the terms of the deal, Lung Cancer Initiative will initially pay an upfront amount of $7.2 million to Pulmatrix. The company will pay an additional amount of $2 million on […]
Pulmatrix Inc (NASDAQ:PULM)
Recent Posts
Futuris Company Announces Cancellation of Acquisition of LotusUSA Inc.
Ronaldinho and DRYWORLD Extend Partnership to 2033
Galexxy Holdings Inc., Appoints High Profile Chief Marketing Officer
RemSleep Holdings Inc. Provides a Corporate Update and Correction
Winners Partner “Horse Races Now” App updated in the Apple App Store and Google Play Store allowing its Users to “Bet Now” with VegasWinners Sportsbook Affiliate Partners
Sign Up To Get Our Instant Alerts!

Popular Post
-
Hollywood Star Cuts Enters Into Acquisition Agreement! 192 views
-
FEED EARTH NOW (FEN) ANNOUNCES FOOD WASTE RECYCLING SYSTEM IN CALIFORNIA 134 views
-
Kimberly Goldwin Poised to Become Next President of ABC News 42 views
-
Spotify Records 20% Increase in Paid Subscribers in the Second Quarter 39 views
-
JPMorgan Bringing Back Employees to Work From Office 38 views